Tenax Therapeutics, Inc., a specialty pharmaceutical company, announced that it will share the results from its HELP (Hemodynamic Evaluation of Levosimendan) Study at a scientific forum this fall.

The study, a Phase 2 clinical trial, evaluated the drug Levosimendan’s effects when treating patients with Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

The results were accepted for a Late-Breaking Clinical Trial presentation at the Heart Failure Society of America Annual Scientific Meeting, which will occur from Sept. 30 to Oct. 6, the company said.

“The positive results of the HELP Study represent a major milestone for Tenax and our development of Levosimendan for the treatment of patients suffering from this debilitating illness,” CEO Anthony DiTonno said in a statement.

The CEO added that the results “may represent a potential breakthrough in the treatment of PH-HFpEF patients.”

This month, the company recently reported a net loss of $2.1 million for the second quarter, citing an increase in research and development expenses.

Shares of Tenax (TENX), which jumped in the pre-market, were trading at $1.42 Monday morning, down four cents, or 2.74%.